India, Aug. 12 -- Xilio Therapeutics, Inc. (XLO), a clinical-stage biotechnology company developing masked immuno-oncology therapies, reported second-quarter 2026 financial results and business updates, highlighting FDA clearance of the IND for XTX501 and continued advancement of its masked T cell engager pipeline.
Company Profile
Xilio focuses on developing masked immuno-oncology therapies designed to selectively activate within the tumor microenvironment while reducing systemic side effects. Its pipeline includes XTX501, a bispecific PD-1/masked IL-2, masked T cell engagers targeting CLDN18.2 and PSMA+STEAP1, and efarindodekin alfa.
Pipeline Update
XTX501 for Advanced Solid Tumors
Xilio received FDA clearance of its IND application f...